Needham Reiterates Buy on Biogen, Maintains $288 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Biogen (NASDAQ:BIIB) and maintains a $288 price target.
August 01, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Biogen and maintains a $288 price target.
The reiteration of a Buy rating and the maintenance of a $288 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100